Cargando…

Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome

Down syndrome (DS) induces a variable phenotype including intellectual disabilities and early development of Alzheimer’s disease (AD). Moreover, individuals with DS display accelerated aging that affects diverse organs, among them the brain. The Ts65Dn mouse is the most widely used model to study DS...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirstein, Martina, Cambrils, Alba, Segarra, Ana, Melero, Ana, Varea, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470680/
https://www.ncbi.nlm.nih.gov/pubmed/35767135
http://dx.doi.org/10.1007/s11064-022-03659-0
_version_ 1784788897037811712
author Kirstein, Martina
Cambrils, Alba
Segarra, Ana
Melero, Ana
Varea, Emilio
author_facet Kirstein, Martina
Cambrils, Alba
Segarra, Ana
Melero, Ana
Varea, Emilio
author_sort Kirstein, Martina
collection PubMed
description Down syndrome (DS) induces a variable phenotype including intellectual disabilities and early development of Alzheimer’s disease (AD). Moreover, individuals with DS display accelerated aging that affects diverse organs, among them the brain. The Ts65Dn mouse is the most widely used model to study DS. Progressive loss of cholinergic neurons is one of the hallmarks of AD present in DS and in the Ts65Dn model. In this study, we quantify the number of cholinergic neurons in control and Ts65Dn mice, observing a general reduction in their number with age but in particular, a greater loss in old Ts65Dn mice. Increased expression of the m1 muscarinic receptor in the hippocampus counteracts this loss. Cholinergic neurons in the Ts65Dn mice display overexpression of the early expression gene c-fos and an increase in the expression of β-galactosidase, a marker of senescence. A possible mechanism for senescence induction could be phosphorylation of the transcription factor FOXO1 and its retention in the cytoplasm, which we are able to confirm in the Ts65Dn model. In our study, using Ts65Dn mice, we observe increased cholinergic activity, which induces a process of early senescence that culminates in the loss of these neurons. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11064-022-03659-0.
format Online
Article
Text
id pubmed-9470680
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-94706802022-09-15 Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome Kirstein, Martina Cambrils, Alba Segarra, Ana Melero, Ana Varea, Emilio Neurochem Res Original Paper Down syndrome (DS) induces a variable phenotype including intellectual disabilities and early development of Alzheimer’s disease (AD). Moreover, individuals with DS display accelerated aging that affects diverse organs, among them the brain. The Ts65Dn mouse is the most widely used model to study DS. Progressive loss of cholinergic neurons is one of the hallmarks of AD present in DS and in the Ts65Dn model. In this study, we quantify the number of cholinergic neurons in control and Ts65Dn mice, observing a general reduction in their number with age but in particular, a greater loss in old Ts65Dn mice. Increased expression of the m1 muscarinic receptor in the hippocampus counteracts this loss. Cholinergic neurons in the Ts65Dn mice display overexpression of the early expression gene c-fos and an increase in the expression of β-galactosidase, a marker of senescence. A possible mechanism for senescence induction could be phosphorylation of the transcription factor FOXO1 and its retention in the cytoplasm, which we are able to confirm in the Ts65Dn model. In our study, using Ts65Dn mice, we observe increased cholinergic activity, which induces a process of early senescence that culminates in the loss of these neurons. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11064-022-03659-0. Springer US 2022-06-29 2022 /pmc/articles/PMC9470680/ /pubmed/35767135 http://dx.doi.org/10.1007/s11064-022-03659-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Kirstein, Martina
Cambrils, Alba
Segarra, Ana
Melero, Ana
Varea, Emilio
Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
title Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
title_full Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
title_fullStr Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
title_full_unstemmed Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
title_short Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
title_sort cholinergic senescence in the ts65dn mouse model for down syndrome
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470680/
https://www.ncbi.nlm.nih.gov/pubmed/35767135
http://dx.doi.org/10.1007/s11064-022-03659-0
work_keys_str_mv AT kirsteinmartina cholinergicsenescenceinthets65dnmousemodelfordownsyndrome
AT cambrilsalba cholinergicsenescenceinthets65dnmousemodelfordownsyndrome
AT segarraana cholinergicsenescenceinthets65dnmousemodelfordownsyndrome
AT meleroana cholinergicsenescenceinthets65dnmousemodelfordownsyndrome
AT vareaemilio cholinergicsenescenceinthets65dnmousemodelfordownsyndrome